NRX Therapeutics Inc Share Price Today: Live Updates & Key Insights

NRX Therapeutics Inc share price today is $1.81, up 0.54%. The stock opened at $1.815 against the previous close of $1.84, with an intraday high of $1.905 and low of $1.79.

NRX Therapeutics Inc Share Price Chart

NRX Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

NRX Therapeutics Inc Share Price Performance

$1.81 0.0054(0.54%) NRXP at 23 Mar 2026 02:30 PM Biotechnology
Lowest Today 1.79
Highest Today 1.905
Today’s Open 1.815
Prev. Close 1.84
52 Week High 3.84
52 Week Low 1.58
Day’s Range: Low 1.79 High 1.905
52-Week Range: Low 1.58 High 3.84
1 day return -
1 Week return -12.25
1 month return +3.69
3 month return -23.64
6 month return -36.96
1 year return -11.19
3 year return -73.16
5 year return -99.32
10 year return -

NRX Therapeutics Inc Institutional Holdings

Anson Funds Management LP 9.55

Vanguard Group Inc 2.29

Vanguard Total Stock Mkt Idx Inv 1.62

AdvisorShares Psychedelics ETF 1.16

Commonwealth Equity Services Inc 1.15

AdvisorShares Investments, LLC 1.03

Geode Capital Management, LLC 0.69

Vanguard Institutional Extnd Mkt Idx Tr 0.56

UBS Group AG 0.48

Fidelity Extended Market Index 0.34

State Street Corp 0.24

BlackRock Inc 0.21

iShares Micro-Cap ETF 0.17

Mandarine Global Microcap G EUR 0.13

Global Retirement Partners, LLC. 0.12

Jane Street Group LLC 0.12

One Wealth Management Investment & Advisory Services LLC 0.12

Chicago Partners Investment Group LLC 0.10

Fidelity Total Market Index 0.10

Northern Trust Corp 0.09

Fidelity Series Total Market Index 0.08

Fidelity Nasdaq Composite Index 0.07

Vanguard Balanced Index Inv 0.06

Spartan Extended Market Index Pool F 0.06

Two Sigma Investments LLC 0.05

Spartan Total Market Index Pool G 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

SJBENEN ADVISORY, LLC 0.05

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Ethos Financial Group LLC 0.04

Morgan Stanley - Brokerage Accounts 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Blackrock Extended Mkt Fund CF 0.02

Bank of America Corp 0.01

SBI Securities Co Ltd 0.01

Wells Fargo & Co 0.01

NRX Therapeutics Inc Market Status

Strong Buy: 3

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

NRX Therapeutics Inc Fundamentals

Market Cap 58.96 M

PB Ratio 2.9042

PE Ratio 0.0

Enterprise Value 61.39 M

Total Assets 3.65 M

Volume 807933

NRX Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-907406 -0.9M, FY19:null 0.0M

Annual Net worth FY23:-36059000 -36.1M, FY22:-35235000 -35.2M, FY21:-71715000 -71.7M, FY20:-12347000 -12.3M, FY19:408427 0.4M

Quarterly Revenue Q3/2025:242000 0.2M, Q2/2025:0 0.0M, Q1/2025:4000 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:145000 0.1M, Q2/2025:null 0.0M, Q1/2025:2000 0.0M, Q3/2024:null 0.0M, Q2/2024:-1000 -0.0M

Quarterly Net worth Q3/2025:-5890000 -5.9M, Q2/2025:-17581000 -17.6M, Q1/2025:-5512000 -5.5M, Q3/2024:-1623000 -1.6M, Q2/2024:-7897000 -7.9M

About NRX Therapeutics Inc & investment objective

Company Information NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital; and has as a partnership with neurocare Group AG to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Dr. Jonathan C. Javitt M.D., M.P.H.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

NRX Therapeutics Inc FAQs

What is the share price of NRX Therapeutics Inc today?

The current share price of NRX Therapeutics Inc is $1.81.

Can I buy NRX Therapeutics Inc shares in India?

Yes, Indian investors can buy NRX Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy NRX Therapeutics Inc shares in India?

You can easily invest in NRX Therapeutics Inc shares from India by:

Can I buy fractional shares of NRX Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of NRX Therapeutics Inc?

NRX Therapeutics Inc has a market cap of $58.96 M.

In which sector does NRX Therapeutics Inc belong?

NRX Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in NRX Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of NRX Therapeutics Inc?

The PE ratio of NRX Therapeutics Inc is N/A and the PB ratio is 2.90.